MILAN, September 20, 2016 /PRNewswire/ --
Zambon SpA, the pharmaceutical company of the group Zambon, has appointed Roberto Tascione as new CEO to drive the business on a global scale.
Tascione, 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol Myers Squibb as President and Chief Executive Officer Italy. Tascione also served on the General Council of Confindustria and was member of Farmindustria Board and the Committee for the Ethical Code.
"Zambon is a leading Italian excellence, with a strong tradition and a strong international outlook dating back to the '50s," said Tascione . " I am very proud to drive the company in this new stage of growth, look at new business opportunities and strengthen our international network."
Elena Zambon, President of Zambon Spa, commented "I believe that a company with 110 years of history needs to rethink its role in providing innovative therapeutic solutions to patients. We are sure that Roberto Tascione with his long-standing experience in this sector will help us reach important goals. With him we share the vision of an Open Company model that puts great attention to the development of internal talent in order for them to become agents of change."
Zambon is an Italian family business operating in the pharmaceutical and fine chemicals for 110 years with more than 2,800 employees in 19 countries in 3 continents, Europe, America and Asia. In 2015 the Group reported revenues for 670 million Euro, with 566.9 million Euro resulting from the pharmaceutical business. Founded in 1906 in Vicenza, Zambon has earned over the years a strong international reputation thanks to its high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care in addition to orphan drugs such as cystic fibrosis and treatments for Parkinson's Disease in the Central Nervous System. Zambon manufacturing is done in Italy, Switzerland, France, Brazil and China and its products are commercialized in 84 countries. For more information: http://www.zambongroup.com.
Luca Primavera - CCO
Milva Naguib - Media Relations